DelveInsight's latest report reveals a robust pipeline for androgenetic alopecia with 80+ companies developing 100+ therapeutic candidates across various clinical stages.

Virios Therapeutics and Wex Pharmaceuticals have merged in an all-stock transaction, creating Dogwood Therapeutics (NASDAQ: DWTX), focused on clinical development of Halneuron®, IMC-1, and IMC-2.

Alnylam Pharmaceuticals Inc discussed their Q3 2024 earnings, focusing on advancements in RNAi therapeutics delivery, the progress of ALN-HTT02 in Phase 1 studies, market dynamics in the polyneuropathy sector, payer discussions for AMVUTTRA, and SG&A spending for upcoming launches.

A Phase I trial of LYMPHIR with pembrolizumab demonstrates a 27% objective response rate in patients with recurrent solid tumors.

Syros Pharmaceuticals anticipates pivotal complete response (CR) data from the SELECT-MDS-1 trial of tamibarotene in higher-risk myelodysplastic syndrome (HR-MDS) by mid-November 2024.